Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on healthrelated quality of life

Authors Marc Miravitlles, Carles Llor, Jesús Molina, et al

Published Date January 2010 Volume 2010:5 Pages 11—19

DOI http://dx.doi.org/10.2147/COPD.S8732

Published 15 January 2010

Marc Miravitlles1, Carles Llor2, Jesús Molina3, Karlos Naberan4, Josep M Cots5, Fernando Ros6 on behalf of the EVOCA Study Group

1Fundació Clínic. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Primary Health Care Center ‘Jaume I’, Societat Catalana de Medicina Familiar i Comunitària, Universitat Rovira i Virgili, Tarragona, Spain; 3Primary Health Care Center ‘Francia’, Grupo de Respiratorio de la Sociedad Madrileña de Medicina Familiar y Comunitaria, Madrid, Spain; 4Primary Health Care Center ‘Fuentes de Ebro’, Grupo de Investigación del Instituto Aragonés Ciencias de la Salud (IACS), Zaragoza, Spain; 5Primary Health Care Center ‘La Marina’, Societat Catalana de Medicina Familiar i Comunitària, Facultat de Medicina, Barcelona, Spain; 6Medical Department, Bayer Healthcare, Barcelona, Spain

Objective: To investigate the impact of exacerbations in health-related quality of life (HRQL) of patients with COPD and to compare the effect of treatment of COPD exacerbations with moxifloxacin (400 mg/day for 5 days) and amoxicillin/clavulanate (500/125 mg 3 times a day for 10 days) on HRQL.

Methods: 229 outpatients with stable COPD (mean age 68.2 years; mean FEV1 % predicted 49.3%) participated in a prospective, observational study of 2 years’ duration. The St George’s Respiratory Questionnaire (SGRQ) was completed at baseline and every 6 months thereafter.

Results: COPD exacerbations (mean 2.7 episodes/patient) occurred in 136 patients (124 patients received the study medications [amoxicillin/clavulanate 54, moxifloxacin 70]). Differences between baseline and the final visit were higher for moxifloxacin compared with amoxicillin/clavulanate for total SGRQ score (-2.60 [13.1] vs 4.21 [16.2], P = 0.05) and “Symptoms” subscale (-5.64 [16.7] vs 8.27 [21], P = 0.02). The same findings were observed in patients with two or more exacerbations.

Conclusions: In COPD outpatients, treatment of exacerbations with moxifloxacin had a more favorable long-term effect on quality of life than amoxicillin/clavulanate.
Keywords: COPD, exacerbations, moxifloxacin, amoxicillin/clavulanate, quality of life, SGRQ

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 15 September 2008

Readers of this article also read:

A score to predict short-term risk of COPD exacerbations (SCOPEX)

Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:201-209

Published Date: 27 January 2015

A pilot randomized controlled trial using EEG-based brain–computer interface training for a Chinese-speaking group of healthy elderly

Lee TS, Quek SY, Goh SJA, Phillips R, Guan C, Cheung YB, Feng L, Wang CC, Chin ZY, Zhang H, Lee J, Ng TP, Krishnan KRR

Clinical Interventions in Aging 2015, 10:217-227

Published Date: 9 January 2015

Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads

Schroyen S, Adam S, Jerusalem G, Missotten P

Clinical Interventions in Aging 2015, 10:117-125

Published Date: 31 December 2014

Does food insufficiency in childhood contribute to dementia in later life?

Momtaz YA, Haron SA, Hamid TA, Ibrahim R, Masud J

Clinical Interventions in Aging 2015, 10:49-53

Published Date: 17 December 2014

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model

Ackerman S, D'Ambrosio, Jr F, Greiner JV, Villanueva L, Ciolino JB, Hollander DA

Journal of Asthma and Allergy 2013, 6:43-52

Published Date: 8 April 2013

Modified supracricoid laryngectomy: oncological and functional outcomes in the elderly

Allegra E, Franco T, Trapasso S, Domanico R, La Boria A, Garozzo A

Clinical Interventions in Aging 2012, 7:475-480

Published Date: 8 November 2012

Development and implementation of treadmill exercise testing protocols in COPD

Christopher B Cooper, Marlon Abrazado, Daniel Legg, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:375-385

Published Date: 12 October 2010

30-days mortality in patients with perforated peptic ulcer: A national audit

Anne Nakano, Jørgen Bendix, Sven Adamsen, Daniel Buck, Jan Mainz, et al

Risk Management and Healthcare Policy 2008, 1:31-38

Published Date: 30 November 2008